B. Braun Closed Interventional Systems Division
The Bethlehem-based manufacturer is cutting 40 jobs as it pivots to focus on core business priorities.
Updated on Oct. 10, 2026 in Healthcare
Live Poll
Do you feel the local job market is getting worse due to recent corporate layoffs?
B. Braun has announced the closure of its Interventional Systems division, a move impacting 40 employees nationwide. The decision is part of a broader corporate strategy to concentrate resources on core business operations.
Why it matters
This shutdown reflects a tightening of operational focus for the medical device firm as it pivots away from its interventional radiology and cardiology product lines. The shift allows the company to reallocate resources toward its primary business interests while exiting specialized niche markets.
The closure affects 40 employees at the B. Braun Interventional Systems division, which follows the loss of 173 jobs across two sites in Upper Macungie Township in June 2026. The division’s commercial sales are slated to cease in early 2027.
The players
B. Braun
A global medical device and pharmaceutical company that provides healthcare products for anesthesia, intensive care, and surgery.
QuVa Pharma Inc.
A manufacturer of sterile compounded medications that serves hospitals and health systems.
The details
B. Braun will manage the shutdown through a phased transition that seeks to minimize service disruptions for current customers. The company is actively coordinating with its supply chain partners to ensure an orderly handoff of existing product lines to new distributors. This operational pivot formalizes the company’s exit from the development of medical devices used in fields like vascular surgery and pulmonology.
Timeline
June 2026: B. Braun closed two sites in Upper Macungie Township.
September 2026: QuVa Pharma acquired medications from Central Admixture Pharmacy Services.
October 9, 2026: The company officially announced the division closure.
Early 2027: Commercial sales for the division are expected to end.
March 2027: All deliveries from the division will conclude.
Market Landscape
This move marks a continued consolidation for B. Braun following the closure of two facilities in Upper Macungie Township in June 2026. The shift signals a deeper commitment to streamlining operations after previous regional downsizing efforts.
Operators currently relying on B. Braun for interventional radiology or cardiology products should review their procurement contracts to identify new distribution sources before March 2027. Businesses should monitor upcoming supply chain communications to ensure their medical inventory remains unaffected by the transition.
The takeaway
Companies should view this transition as a prompt to audit supply chain resilience when specialized suppliers consolidate their offerings. Managers should confirm that their primary vendors have stable product support roadmaps for the next two fiscal quarters.
Further reading
For additional context on regional medical device operations, see our coverage of Healthcare.
Live Poll
Do you feel the local job market is getting worse due to recent corporate layoffs?
